Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-TARD-001 in ALS due to TARDBP mutation
NCT07095712Phase 2Completed
- Sponsor
- n-Lorem Foundation
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of NL-TARD-001 in amyotrophic lateral sclerosis (ALS), sponsored by n-Lorem Foundation. Started Nov 2024; status: completed.
02
Drugs
NL-TARD-001
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07095712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095712.